Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations

Lung adenocarcinoma (LUAD) is the most prevalent subtype of non‐small cell lung cancer. Despite the development of novel targeted and immune therapies, the 5‐year survival rate is still only 21%, indicating the need for more efficient treatment regimens. Lysine‐specific demethylase 1 (LSD1) is an ep...

Descripción completa

Detalles Bibliográficos
Autores principales: Macheleidt, Iris F., Dalvi, Priya S., Lim, So‐Young, Meemboor, Sonja, Meder, Lydia, Käsgen, Olivia, Müller, Marion, Kleemann, Karolin, Wang, Lingyu, Nürnberg, Peter, Rüsseler, Vanessa, Schäfer, Stephan C., Mahabir, Esther, Büttner, Reinhard, Odenthal, Margarete
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210049/
https://www.ncbi.nlm.nih.gov/pubmed/30220105
http://dx.doi.org/10.1002/1878-0261.12382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210049/
https://www.ncbi.nlm.nih.gov/pubmed/30220105
http://dx.doi.org/10.1002/1878-0261.12382

Ejemplares similares